Novel Therapeutic Approaches to Multiple Sclerosis: Neuroprotective Drugs for Relapsing-Remitting Multiple Sclerosis

Q4 Immunology and Microbiology
M. Pugliese, J. Espinosa-Parrilla, J. Bustos, C. Campás, M. Frias, Georgina Sorrosal
{"title":"Novel Therapeutic Approaches to Multiple Sclerosis: Neuroprotective Drugs for Relapsing-Remitting Multiple Sclerosis","authors":"M. Pugliese, J. Espinosa-Parrilla, J. Bustos, C. Campás, M. Frias, Georgina Sorrosal","doi":"10.3233/NIB-130066","DOIUrl":null,"url":null,"abstract":"Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS) that causes significant disability. Immunosuppressive and immunomodulatory drugs have been designed for years to treat MS, as it was considered the most appropriate way to balance the effects of the patients' immune reaction. However, basic and clinical research has recently offered new data that help to better understand the nature of this complex disease, allowing changing the treatment approach. As a consequence, the first disease-modifying drug with a suggested neuroprotective and antioxidative mechanism of action has been recently approved, broadening and improving the therapeutic landscape to fight against MS. In this review, we focused our attention on promising neuroprotective or neuroregenerative drugs that are currently approved or in clinical trials. These neuroprotective therapies provide new valid alternatives that significantly could impact on disease progression and neurodegenerative changes in MS.","PeriodicalId":38645,"journal":{"name":"Advances in Neuroimmune Biology","volume":"4 1","pages":"187-204"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/NIB-130066","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Neuroimmune Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/NIB-130066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS) that causes significant disability. Immunosuppressive and immunomodulatory drugs have been designed for years to treat MS, as it was considered the most appropriate way to balance the effects of the patients' immune reaction. However, basic and clinical research has recently offered new data that help to better understand the nature of this complex disease, allowing changing the treatment approach. As a consequence, the first disease-modifying drug with a suggested neuroprotective and antioxidative mechanism of action has been recently approved, broadening and improving the therapeutic landscape to fight against MS. In this review, we focused our attention on promising neuroprotective or neuroregenerative drugs that are currently approved or in clinical trials. These neuroprotective therapies provide new valid alternatives that significantly could impact on disease progression and neurodegenerative changes in MS.
多发性硬化的新治疗方法:复发-缓解型多发性硬化的神经保护药物
多发性硬化症(MS)是中枢神经系统(CNS)的一种慢性炎症性和退行性疾病,可导致严重的残疾。免疫抑制和免疫调节药物多年来一直被设计用于治疗多发性硬化症,因为它被认为是平衡患者免疫反应影响的最合适方法。然而,基础和临床研究最近提供了新的数据,有助于更好地了解这种复杂疾病的性质,从而改变治疗方法。因此,第一种具有神经保护和抗氧化作用机制的疾病改善药物最近被批准,扩大和改善了对抗ms的治疗前景。在本综述中,我们将重点关注目前已批准或处于临床试验中的有前景的神经保护或神经再生药物。这些神经保护疗法提供了新的有效的替代方案,可以显著影响MS的疾病进展和神经退行性改变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Neuroimmune Biology
Advances in Neuroimmune Biology Immunology and Microbiology-Immunology
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信